Snappy newsletters. Simple Facebook sharing. Spirited comments. Sweet features are waiting… GET THEM NOW!

Antidepressant Studies Distort Drugs' Usefulness

New study says negative reports often go unpublished

By Wesley Oliver, Newser Staff

Posted Jan 16, 2008 9:37 PM CST

(Newser) – Roughly half of the medical studies involving antidepressants that found little or no effect on patients have gone unpublished or had their findings mischaracterized as positive, a new study reveals. The emphasis on publishing only studies with glowing reviews gives patients and doctors a false... Read full story »

COMMENTS

Read the comment policy

You need to Log in to Newser to comment. Don't have an account yet? Sign up now!

There are no comments

A snapshot of the day's best news stories.

View Larger Grid

All Today Yesterday Pick a Date

What's Popular Now on Facebook

Cops Shoot Naked Guy Eating Man's Face on Highway

Japanese Artist Serves Up Own Cooked Genitals

Wall Street Journal (Source Grid »)

Researchers: "selective publishing" can lead to "inappropriate prescribing decisions"
DogFlu

Zetia oversight not a fluke
Clinical Psychology and Psychiatry

Health

FDA • antidepressant • pharmaceutical companies • Pfizer • New England Journal of Medicine • patients • doctor • Zoloft • Wyeth • Effexor

More Newser Stories

Feds OK Wyeth's New Antidepressant

Faced with generic threats to its popular Effexor XR, company banking on Pristiq

(NEWSER) - Antidepressant Effexor XR will soon lose patent protection, and maker Wyeth is hoping Pristiq, the successor drug approved today by the FDA, will soften the financial blow. Higher-ups at the company gush over Pristiq's advantages, including zero acclimation time and no liver interaction, and hope that sales will offset losses to generic versions of Effexor, the New York Times reports. More»

Anti-Smoking Chantix, Zyban Pose Suicide Risk: FDA

Smokers with mental illnesses should avoid them, agency says

(NEWSER) - The Food and Drug Administration is warning smokers about serious mental-illness risks of two smoking-cessation drugs, as reported suicides among their users increase. Chantix and Zyban must now carry the agency’s strongest warning label, the New York Times reports. The FDA isn’t trying to scare patients, an official says: “You should just be careful.” More»

Pfizer Deal's $22.5B in Loans Hasn't Unlocked Credit

$22.5B loan in deal to acquire Wyeth comes at 7-9% interest, and lenders can walk

(NEWSER) - Think Pfizer’s $68 billion deal to buy Wyeth, financed in part with $22.5 billion in loans, means credit markets have thawed? Think again, the Wall Street Journal reports. Pfizer’s lenders—including JPMorgan, Bank of America, Goldman, and Citigroup—are charging high interest (7%-9%, with loans due in a year) and can walk if Pfizer’s credit rating drops below investment-grade. More»

Pfizer Snaps Up Wyeth for $68B

Merger would be largest pharma deal since GlaxoWellcome-SmithKline 2000 merger

(NEWSER) - The world’s largest drugmaker, Pfizer, is poised to become even more gargantuan after it agreed early this morning to buy rival Wyeth for $68 billion, reports the Wall Street Journal. In the first major merger to hit Wall Street in months, Pfizer will borrow $22.5 billion from four banks that received bailout money—Goldman Sachs, JPMorgan, Citigroup, and Bank of America, reports the New York Times. More»

Pfizer in Talks to Buy Wyeth

Sources say drug maker plans $60B acquisition of rival Wyeth

(NEWSER) - Pfizer is seeking to create a Big Pharma behemoth with the acquisition of rival Wyeth, insiders tell the Wall Street Journal. The deal, expected to be worth around $60 billion, would make Pfizer—already the world's biggest drug company—big enough to redraw the map of the industry, although sources say the state of the economy means the talks could still collapse. More»

NEWS FROM OUR PARTNERS

What is Newser?

Face it: there's too much news. At Newser, we choose the most thought-provoking and entertaining stories from hundreds of US and international sources and reduce them to a headline, picture, and two paragraphs. And we do it 24/7—you can come back morning, noon, night (and in between) for something new that matters. Read less, know more.

Learn more »

Partnering with: Slate

View Newser on the mobile website

Antidepressant Studies Distort Drugs' Usefulness

New study says negative reports often go unpublished

FDA • antidepressant • pharmaceutical companies • Pfizer • New England Journal of Medicine • patients • doctor • Zoloft • Wyeth • Effexor

MOST POPULAR STORIES

[ By Views ]

[ By Comments ]

More Newser Stories

Feds OK Wyeth's New Antidepressant

Faced with generic threats to its popular Effexor XR, company banking on Pristiq

Anti-Smoking Chantix, Zyban Pose Suicide Risk: FDA

Smokers with mental illnesses should avoid them, agency says

Pfizer Deal's $22.5B in Loans Hasn't Unlocked Credit

$22.5B loan in deal to acquire Wyeth comes at 7-9% interest, and lenders can walk

Pfizer Snaps Up Wyeth for $68B

Merger would be largest pharma deal since GlaxoWellcome-SmithKline 2000 merger

Pfizer in Talks to Buy Wyeth

Sources say drug maker plans $60B acquisition of rival Wyeth

About Us

Site

Community

Site Maps

Tools

More News

What is Newser?